For six years, the Psoriasis Longitudinal Assessment and Registry (PSOLAR) has collected data to assess the infection risk for drugs treating systemic psoriasis.
NEW YORK (Reuters Health)—Real-world psoriasis patients receiving biologic therapies rarely stop taking the drugs because of adverse effects, researchers say. Although data from long-term registries have shown similar results, “the demographics of patients in registries are somewhat different than those of patients in real-world practices,” Dr. Jensen Yeung told Reuters Health by email. “I have…
LONDON (Reuters)—AstraZeneca’s hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller. Amgen, its partner on the project, announced late on Friday it was ending a collaboration to develop brodalumab after suicidal…
The Arthritis Foundation and the National Psoriasis Foundation launched the Joint Smart Coalition to focus on patient education, resources, and outreach. At a coalition-sponsored community-outreach event at Queens College in Flushing, N.Y., attendees were provided information on setting goals, stretching techniques, easy exercises, treatment options, and tips for a healthy lifestyle. (posted Dec. 13)
Investigators have described 15 new psoriasis susceptibility loci. The loci highlight the importance of the skin in both acquired and innate host defense and identify the innate immune response as a key factor in psoriasis.